Clinical Trials on Severe Haemophilia

Total 4750 results

Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
UMC Utrecht

Unknown

Cardiovascular Disease (CVD) in Haemophilia

Cardiovascular Disease | Haemophilia

Netherlands, United Kingdom
The Hospital for Sick Children
Baxter Healthcare Corporation; University of Sao Paulo; University of Campinas... and other collaborators

Completed

Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles

Hemophilia | Hemophilic Arthropathy

Canada, Brazil
PD Dr. Andreas Strauß
Bayer

Recruiting

Osteoporosis and Haemophilia

Osteoporosis | Haemophilia | Bone Mass

Germany
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
University of the Philippines
World Health Organization; University of North Carolina; International Vaccine... and other collaborators

Active, not recruiting

Dengue Serostatus Study in the Philippines

Dengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
Necmettin Erbakan University

Completed

Effectiveness of Manual Therapy and Strengthening Exercises in Hemophilic Arthropathy of the Elbow Joint

Hemophilia | Arthritis

Turkey
Necmettin Erbakan University

Completed

The Effects of Manual Therapy in Hemophilic Patients

Hemophilia | Arthropathy Hemophilic

Turkey
Novo Nordisk A/S

Completed

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Congenital Bleeding Disorder | Haemophilia A

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
Novo Nordisk A/S

Completed

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

Spain, Germany, Switzerland, Italy, Israel
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (pathfinder™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Germany, Switzerland, United Kingdom, Italy, Japan, Turkey
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

Spain, Germany, Malaysia, Latvia
Novo Nordisk A/S

Completed

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

United Kingdom, Malaysia
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Macedonia, The Former Yugoslav Republic of, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Israel, Russian Federation, Turkey, Lithuania, Poland, Japan, Latvia, Puerto...
Tongji Hospital

Recruiting

A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome

Severe Fever With Thrombocytopenia Syndrome

China
Qin Ning

Recruiting

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Severe Fever With Thrombocytopenia Syndrome

China
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Universidad Católica San Antonio de Murcia

Unknown

Myofascial Therapy in Patients With Hemophilic Arthropathy (He-Fascial)

Hemophilia

Spain
Tri-Service General Hospital

Completed

PET Imaging of Hemophilic Arthropathy

Inflammation | Hemophilia | Arthropathy

Taiwan
University of Sao Paulo General Hospital

Completed

Viscosupplementation in Patients With Hemophilic Arthropathy

Hemophilia A | Hemophilia B | Osteoarthritis | Hemarthrosis

Brazil
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Acquired Bleeding Disorder | Dengue Haemorrhagic Fever

Malaysia, Philippines, Thailand
Nantes University Hospital

Completed

Gait Analysis in Moderate Hemophiliac Patients (AQM-Hemophile)

Arthropathy | Moderate Hemophilia

France
Catalyst Biosciences

Completed

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Hemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

Bulgaria, Russian Federation
Indiana Hemophilia &Thrombosis Center, Inc.
Genentech, Inc.

Terminated

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

Haemophilic Pseudotumour

United States
Bayer

Completed

A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Hemophilia A; Hemophilia B

Israel
GWT-TUD GmbH
Hannover Medical School; Hoffmann-La Roche

Completed

Emicizumab in Acquired Hemophilia A

Hemophilia A, Acquired

Austria, Germany
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Pfizer

Completed

Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

Factor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
University of British Columbia
Biogen

Completed

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Hemophilia A, Congenital | Hemophilia B, Congenital

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Human Immunodeficiency Virus | Dengue Fever | Dengue Hemorrhagic Fever

Brazil
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
AryoGen Pharmed Co.

Completed

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Iran, Islamic Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
University of Washington
Genentech, Inc.

Recruiting

Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)

Acquired Hemophilia A

United States
Baxalta now part of Shire

No longer available

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A

United States
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States, United Kingdom, Taiwan, Italy, Spain, India, Turkey, Malaysia, Russian Federation, Armenia, Georgia, Hungary, Mexico, Poland, South Africa, Ukraine
Jiangsu Gensciences lnc.

Recruiting

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Hemophilia | Hemophilia A With Inhibitor | Male | Hemophilia B With Inhibitor

China

Clinical Trials on Severe Haemophilia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations